The Evolution and Future Directions of Targeted Therapy for Advanced G
The evolution and future directions of targeted therapy for advanced gastrointestinal stromal tumor (GIST) are discussed, focusing on sequencing of tyrosine‑kinase inhibitors and emerging resistance mechanisms.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, with its pathogenesis primarily linked to activating mutations in the KIT or platelet derived growth factor receptor alpha (PDGFRA) genes. Surgical resection remains the standard curative treatment for localized GIST; however, ~50% of patients eventually develop recurrence or metastasis. Since the introduction of imatinib in the early 21st century, the management of metastatic GIST has shifted from solely surgical intervention to a systemic, chronic disease management model centered on tyrosine kinase inhibitors (TKIs). ...
Advances in targeted therapy have substantially improved survival for patients with advanced GIST, yet drug resistance remains a major obstacle, underscoring the need for novel therapeutic strategies.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)